TY - JOUR
T1 - Shigella depends on SepA to destabilize the intestinal epithelial integrity via cofilin activation
AU - Maldonado-Contreras, Ana
AU - Birtley, James R.
AU - Boll, Erik
AU - Zhao, Yun
AU - Mumy, Karen L.
AU - Toscano, Juan
AU - Ayehunie, Seyoum
AU - Reinecker, Hans Christian
AU - Stern, Lawrence J.
AU - McCormick, Beth A.
N1 - Funding Information:
This work was supported by: AM-C by the Charles A. King Trust Postdoctoral Research Fellowship Program and the Faculty Diversity Scholar Program at UMASS Medical School; EB by the Carlsberg Foundation; HCR and YZ by National Institutes of Health (NIH) Grants: AI113333, DK068181, and DK043351; BAM, AM-C and KLM by NIH Grants: DK56754 and DK33506; LJS and JRB by NIH AI-38996.
Funding Information:
This study used resources provided by the Advanced Photon Source, a US. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02– 06CH11357. We acknowledge the use of the Lilly Research Laboratories Collaborative Access Team (LRL-CT) beamline at Sector 31 of the Advanced Photon Source provided by Eli Lilly Company. We thank Zachary Maben for assistance with preparation of samples for the synchrotron.
Funding Information:
This study used resources provided by the Advanced Photon Source, a US. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02?06CH11357. We acknowledge the use of the Lilly Research Laboratories Collaborative Access Team (LRL-CT) beamline at Sector 31 of the Advanced Photon Source provided by Eli Lilly Company. We thank Zachary Maben for assistance with preparation of samples for the synchrotron. This work was supported by: AM-C by the Charles A. King Trust Postdoctoral Research Fellowship Program and the Faculty Diversity Scholar Program at UMASS Medical School; EB by the Carlsberg Foundation; HCR and YZ by National Institutes of Health (NIH) Grants: AI113333, DK068181, and DK043351; BAM, AM-C and KLM by NIH Grants: DK56754 and DK33506; LJS and JRB by NIH AI-38996.
Publisher Copyright:
© 2017 Taylor & Francis.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - Shigella is unique among enteric pathogens, as it invades colonic epithelia through the basolateral pole. Therefore, it has evolved the ability to breach the intestinal epithelial barrier to deploy an arsenal of effector proteins, which permits bacterial invasion and leads to a severe inflammatory response. However, the mechanisms used by Shigella to regulate epithelial barrier permeability remain unknown. To address this question, we used both an intestinal polarized model and a human ex-vivo model to further characterize the early events of host-bacteria interactions. Our results showed that secreted Serine Protease A (SepA), which belongs to the serine protease autotransporter of Enterobacteriaceae family, is responsible for critically disrupting the intestinal epithelial barrier. Such disruption facilitates bacterial transit to the basolateral pole of the epithelium, ultimately fostering the hallmarks of the disease pathology. SepA was found to cause a decrease in active LIM Kinase 1 (LIMK1) levels, a negative inhibitor of actin-remodeling proteins, namely cofilin. Correspondingly, we observed increased activation of cofilin, a major actin-polymerization factor known to control opening of tight junctions at the epithelial barrier. Furthermore, we resolved the crystal structure of SepA to elucidate its role on actin-dynamics and barrier disruption. The serine protease activity of SepA was found to be required for the regulatory effects on LIMK1 and cofilin, resulting in the disruption of the epithelial barrier during infection. Altogether, we demonstrate that SepA is indispensable for barrier disruption, ultimately facilitating Shigella transit to the basolateral pole where it effectively invades the epithelium.
AB - Shigella is unique among enteric pathogens, as it invades colonic epithelia through the basolateral pole. Therefore, it has evolved the ability to breach the intestinal epithelial barrier to deploy an arsenal of effector proteins, which permits bacterial invasion and leads to a severe inflammatory response. However, the mechanisms used by Shigella to regulate epithelial barrier permeability remain unknown. To address this question, we used both an intestinal polarized model and a human ex-vivo model to further characterize the early events of host-bacteria interactions. Our results showed that secreted Serine Protease A (SepA), which belongs to the serine protease autotransporter of Enterobacteriaceae family, is responsible for critically disrupting the intestinal epithelial barrier. Such disruption facilitates bacterial transit to the basolateral pole of the epithelium, ultimately fostering the hallmarks of the disease pathology. SepA was found to cause a decrease in active LIM Kinase 1 (LIMK1) levels, a negative inhibitor of actin-remodeling proteins, namely cofilin. Correspondingly, we observed increased activation of cofilin, a major actin-polymerization factor known to control opening of tight junctions at the epithelial barrier. Furthermore, we resolved the crystal structure of SepA to elucidate its role on actin-dynamics and barrier disruption. The serine protease activity of SepA was found to be required for the regulatory effects on LIMK1 and cofilin, resulting in the disruption of the epithelial barrier during infection. Altogether, we demonstrate that SepA is indispensable for barrier disruption, ultimately facilitating Shigella transit to the basolateral pole where it effectively invades the epithelium.
KW - LIM Kinases
KW - SPATEs
KW - SepA
KW - Shigella
KW - cofilin
UR - http://www.scopus.com/inward/record.url?scp=85021425644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021425644&partnerID=8YFLogxK
U2 - 10.1080/19490976.2017.1339006
DO - 10.1080/19490976.2017.1339006
M3 - Article
C2 - 28598765
AN - SCOPUS:85021425644
SN - 1949-0976
VL - 8
SP - 544
EP - 560
JO - Gut Microbes
JF - Gut Microbes
IS - 6
ER -